The NeurologyLive® epilepsy clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to epilepsy and related epileptic conditions, including Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, focal seizures, nonmotor seizures, and more.
August 26th 2025
Spanning across the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have data readout by the end of 2027.
Building a Vibrant Community of Neurology Educators: Tracey Milligan, MD, MS, FAAN, FANA, FAES
Published: June 30th 2024 | Updated: July 1st 2024The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]
NeurologyLive® Clinician of the Month Spotlight: Danielle Andrade, MD, MSc, FRCPC
June 28th 2024As part of our monthly clinician spotlight, NeurologyLive® highlighted seizure disorder expert Danielle Andrade, MD, MSc, FRCPC, director of the Adult Genetic Epilepsy Program at the University of Toronto.
Nocturnal Hypoxia and Sleep Apnea Associated With Late-Onset Epilepsy
Published: June 18th 2024 | Updated: June 19th 2024A recent study showed a significant association between sleep apnea, additional sleep characteristics, and late-onset epilepsy in older adults, even after adjusting for comorbidities.
Mixed Topline Data Reported in Phase 3 RAISE Trial of Ganaxolone for Refractory Status Epilepticus
June 18th 2024Marinus Pharmaceuticals reported that it will continue to analyze the full dataset and engage with the FDA to discuss the future of ganaxolone for treating refractory status epilepticus.
Phase 1/2 Studies Highlight Durable Impacts of Gene Therapy TSHA-102 in Rett Syndrome
June 18th 2024Initial data from a few pediatric and adult patients with Rett syndrome showed that treatment with TSHA-102 resulted in numerous positive enhancements across multiple efficacy measures and clinical domains.